Sung Ji Nam
Stock Analyst at Scotiabank
(3.51)
# 938
Out of 4,734 analysts
63
Total ratings
57.41%
Success rate
3.11%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHR Danaher | Initiates: Sector Perform | $265 | $238.36 | +11.18% | 1 | Dec 23, 2024 | |
| WAT Waters | Initiates: Sector Perform | $430 | $404.00 | +6.44% | 1 | Dec 23, 2024 | |
| TMO Thermo Fisher | Initiates: Sector Perform | $605 | $559.65 | +8.10% | 12 | Dec 23, 2024 | |
| TWST Twist Bioscience | Maintains: Sector Outperform | $50 → $54 | $47.56 | +13.54% | 4 | Nov 19, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $7 → $6 | $1.64 | +265.85% | 4 | Nov 11, 2024 | |
| VCYT Veracyte | Maintains: Sector Outperform | $40 → $44 | $40.58 | +8.43% | 4 | Nov 8, 2024 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $37 → $44 | $24.94 | +76.42% | 5 | Nov 6, 2024 | |
| CDNA CareDx | Maintains: Buy | $40 → $35 | $21.44 | +63.25% | 4 | Nov 5, 2024 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $83 → $88 | $75.83 | +16.05% | 1 | Oct 31, 2024 | |
| BDSX Biodesix | Initiates: Sector Outperform | $3 | $1.15 | +160.87% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $6 → $1 | $0.19 | +417.06% | 5 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $136.67 | +20.00% | 9 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $29 → $34 | $12.39 | +174.41% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $51.74 | +35.29% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $8.07 | -25.65% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $36 | $36.66 | -1.80% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $6.81 | +120.26% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.10 | - | 3 | Nov 24, 2020 |
Danaher
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $238.36
Upside: +11.18%
Waters
Dec 23, 2024
Initiates: Sector Perform
Price Target: $430
Current: $404.00
Upside: +6.44%
Thermo Fisher
Dec 23, 2024
Initiates: Sector Perform
Price Target: $605
Current: $559.65
Upside: +8.10%
Twist Bioscience
Nov 19, 2024
Maintains: Sector Outperform
Price Target: $50 → $54
Current: $47.56
Upside: +13.54%
Pacific Biosciences of California
Nov 11, 2024
Maintains: Sector Outperform
Price Target: $7 → $6
Current: $1.64
Upside: +265.85%
Veracyte
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $40.58
Upside: +8.43%
Castle Biosciences
Nov 6, 2024
Maintains: Sector Outperform
Price Target: $37 → $44
Current: $24.94
Upside: +76.42%
CareDx
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $21.44
Upside: +63.25%
Bio-Techne
Oct 31, 2024
Maintains: Sector Outperform
Price Target: $83 → $88
Current: $75.83
Upside: +16.05%
Biodesix
Sep 16, 2024
Initiates: Sector Outperform
Price Target: $3
Current: $1.15
Upside: +160.87%
Aug 28, 2024
Downgrades: Sector Perform
Price Target: $6 → $1
Current: $0.19
Upside: +417.06%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $136.67
Upside: +20.00%
Aug 13, 2024
Maintains: Sector Outperform
Price Target: $29 → $34
Current: $12.39
Upside: +174.41%
Jun 27, 2024
Initiates: Sector Outperform
Price Target: $70
Current: $51.74
Upside: +35.29%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $8.07
Upside: -25.65%
Jan 5, 2023
Initiates: Sector Outperform
Price Target: $36
Current: $36.66
Upside: -1.80%
Jan 5, 2023
Initiates: Sector Outperform
Price Target: $15
Current: $6.81
Upside: +120.26%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.10
Upside: -